Why the study?
The comparative bleeding and ischemic risks of different antithrombotic regimens in anticoagulated AF patients undergoing PCI were not well characterized.
Does triple antithrombotic therapy compared to dual antithrombotic therapy affect bleeding and ischemic outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention?
Observational (n=647)
Yes
Does triple antithrombotic therapy compared to dual antithrombotic therapy affect bleeding and ischemic outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
In AF patients undergoing PCI, DAT and TAT had similar 1-year bleeding and ischemic outcomes, though prolonging TAT beyond 1 month significantly increased bleeding risk.
GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) registry is a multicenter, observational, non-interventional study of AF patients undergoing PCI. Primary endpoint included clinically significant bleeding rate at 12 months between different antithrombotic regimens prescribed at discharge; secondary endpoints included major adverse cardiovascular events (MACEs) as well as net adverse clinical events (NACEs). A total of 647 patients were analyzed. The majority (92.9%) were discharged on NOACs with only 7.1% receiving VKA. A little over half of patients (50.4%) received triple antithrombotic therapy (TAT) – mostly (62.9%) for ≤ 1 month – while the rest (49.6%) received dual antithrombotic therapy (DAT). Clinically significant bleeding risk was similar between TAT and DAT (HR = 1.08; 95% CI = 0.66 – 1.78), though among TAT-receiving patients, the risk was lower in those receiving TAT for ≤ 1 month (HR = 0.50; 95% CI = 0.25 – 0.99). Anticoagulant choice (NOAC vs VKA) did not significantly affect bleeding rates (P=0.258). Age, heart failure, leukemia/myelodysplasia and acute coronary syndrome were associated with increased bleeding rates. Risk of MACEs and NACEs was similar between ΤAT and DAT (HR = 1.73; 95% CI = 0.95 – 3.18, P = 0.075 and HR = 1.39; 95% CI = 0.93 – 2.08, P=0.106, respectively). In conclusion, clinically significant bleeding and ischemic rates were similar between DAT and TAT, although TAT >1 month was associated with higher bleeding risk.
No takes yet. Share an insight, caveat, or question.
Alexopoulos et al. (2022) conducted an observational in Atrial fibrillation undergoing percutaneous coronary intervention (n=647). Triple antithrombotic therapy (TAT) vs. Dual antithrombotic therapy (DAT) was evaluated on Clinically significant bleeding rate at 12 months (HR 1.08, 95% CI 0.66-1.78).
Synapse has enriched 10 related papers. Consider them for comparative context: